- Conditions
- Surgical Site Infection, Skin Cancer, Wound Healing
- Interventions
- Cyanoacrylate Skin Adhesive, Fast Gut Running Epidermal Suture Closure, Vicryl Rapide Running Epidermal Suture Closure, Prolene Running Epidermal Suture Closure
- Device · Procedure
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 3
- States / cities
- Minneapolis, Minnesota
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 193–216
of 22,439
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Urothelial Carcinoma
- Interventions
- Pembrolizumab & Enfortumab Vedotin (PEV), Pembrolizumab
- Drug
- Lead sponsor
- University of Oklahoma
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma
- Conditions
- Premature Ventricular Contractions
- Interventions
- MIBG nuclear scan
- Other
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Leukemia, Myeloid
- Interventions
- Lenalidomide
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 1 Year to 18 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 56
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 51 more
- Conditions
- Alveolar Soft Part Sarcoma, Angiomatoid Fibrous Histiocytoma, Atypical Fibroxanthoma, Clear Cell Sarcoma of Soft Tissue, Epithelioid Malignant Peripheral Nerve Sheath Tumor, Epithelioid Sarcoma, Extraskeletal Myxoid Chondrosarcoma, Extraskeletal Osteosarcoma, Fibrohistiocytic Neoplasm, Fibrosarcoma, Inflammatory Myofibroblastic Tumor, Intimal Sarcoma, Leiomyosarcoma, Liposarcoma, Liver Embryonal Sarcoma, Low Grade Fibromyxoid Sarcoma, Low Grade Myofibroblastic Sarcoma, Malignant Peripheral Nerve Sheath Tumor, Malignant Skin Granular Cell Tumor, Malignant Triton Tumor, Mesenchymal Chondrosarcoma, Myxofibrosarcoma, Myxoid Chondrosarcoma, Myxoinflammatory Fibroblastic Sarcoma, Nerve Sheath Neoplasm, PEComa, Pericytic Neoplasm, Plexiform Fibrohistiocytic Tumor, Sclerosing Epithelioid Fibrosarcoma, Skin Glomus Tumor, Stage IB Soft Tissue Sarcoma AJCC v7, Stage IIB Soft Tissue Sarcoma AJCC v7, Stage III Soft Tissue Sarcoma AJCC v7, Stage IV Soft Tissue Sarcoma AJCC v7, Synovial Sarcoma, Undifferentiated High Grade Pleomorphic Sarcoma of Bone
- Interventions
- Doxorubicin, Doxorubicin Hydrochloride, Ifosfamide, Pazopanib, Pazopanib Hydrochloride, Radiation Therapy, Therapeutic Conventional Surgery
- Drug · Radiation · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 2 Years and older
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2026
- U.S. locations
- 365
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 240 more
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Blastic Phase Chronic Myelogenous Leukemia, Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission, Childhood Chronic Myelogenous Leukemia, Childhood Myelodysplastic Syndromes, Chronic Phase Chronic Myelogenous Leukemia, de Novo Myelodysplastic Syndromes, Disseminated Neuroblastoma, Juvenile Myelomonocytic Leukemia, Previously Treated Childhood Rhabdomyosarcoma, Previously Treated Myelodysplastic Syndromes, Pulmonary Complications, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Neuroblastoma, Recurrent Wilms Tumor and Other Childhood Kidney Tumors, Recurrent/Refractory Childhood Hodgkin Lymphoma, Relapsing Chronic Myelogenous Leukemia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes
- Interventions
- etanercept, methylprednisolone
- Biological · Drug
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 1 Year to 17 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 26
- States / cities
- Birmingham, Alabama • Arcadia, California • Loma Linda, California + 22 more
- Conditions
- Arrhythmias, Cardiac, Atrial Fibrillation
- Interventions
- Intravenous Sotalol Administered as a Loading Dose to Initiate Oral Sotalol Therapy in Adult Patients with Atrial Fibrillation
- Drug
- Lead sponsor
- Kansas City Heart Rhythm Research Foundation
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Postoperative Pain
- Interventions
- Not listed
- Lead sponsor
- The Medicines Company
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015
- U.S. locations
- 9
- States / cities
- Bridgeport, Connecticut • Jupiter, Florida • Tamarac, Florida + 5 more
- Conditions
- HIV Infections
- Interventions
- PRO 2000
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- U.S. locations
- 1
- States / cities
- Research Triangle Park, North Carolina
- Conditions
- Refractory Multiple Myeloma, Relapsed Multiple Myeloma
- Interventions
- Descartes-15
- Drug
- Lead sponsor
- Cartesian Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Long COVID
- Interventions
- No intervention
- Other
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Abscess
- Interventions
- Nitrous Oxide, Oxygen
- Drug
- Lead sponsor
- Albert Einstein Healthcare Network
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Tiotropium Inhalation Solution, Placebo
- Drug · Other
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 983 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Pismo Beach, California • San Diego, California + 9 more
- Conditions
- Heart Failure, Edema, Pulmonary Congestion, Fluid Overload
- Interventions
- Extended Release Torsemide Tablets, Immedate Release Torsemide Tablets
- Drug
- Lead sponsor
- Sarfez Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Pregnancy, Aneuploidy, Down Syndrome, Edwards Syndrome
- Interventions
- Not listed
- Lead sponsor
- Sequenom, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 2,502 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 30
- States / cities
- Mobile, Alabama • La Mesa, California • San Diego, California + 21 more
- Conditions
- Hypertrophic
- Interventions
- embrace device
- Device
- Lead sponsor
- Neodyne Biosciences, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 13
- States / cities
- Atherton, California • Bakersfield, California • Danville, California + 10 more
- Conditions
- Arrhythmia
- Interventions
- GAP-486 (ZP-123), 0.9% Sodium Chloride, USP
- Drug
- Lead sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 19
- States / cities
- Sacramento, California • San Francisco, California • Washington D.C., District of Columbia + 15 more
- Conditions
- Wrinkle, Acne Scars - Mixed Atrophic and Hypertrophic, Pigmented Lesions, Skin Laxity, Scars
- Interventions
- MIRIA
- Device
- Lead sponsor
- AVAVA, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2026
- U.S. locations
- 2
- States / cities
- Dix Hills, New York • New York, New York
- Conditions
- Congenital Heart Disease, Upper Gastrointestinal Bleeding, Stress Ulcer, Infection
- Interventions
- Famotidine, Placebo
- Drug
- Lead sponsor
- Boston Children's Hospital
- Other
- Eligibility
- 1 Minute to 12 Months
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- budesonide/formoterol, albuterol/salbutamol, FF/UMEC/VI, Placebo to match budesonide/formoterol, tiotropium, Placebo to match FF/UMEC/VI, placebo to match tiotropium, ELLIPTA, MDI, HandiHaler
- Drug · Device
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 729 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 40
- States / cities
- Gold River, California • Clearwater, Florida • DeBary, Florida + 31 more
- Conditions
- Kidney Transplantation, End Stage Renal Disease
- Interventions
- Not listed
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- Not listed
- Enrollment
- 8,951 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 3
- States / cities
- Birmingham, Alabama • Minneapolis, Minnesota • Rochester, Minnesota
- Conditions
- Healthy, Lupus, Celiac, Kidney Disease, Chronic, Dermatologic
- Interventions
- Observation
- Other
- Lead sponsor
- Joined Bio
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 100,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2036
- U.S. locations
- 1
- States / cities
- Lexington, Massachusetts
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- fluticasone propionate/salmeterol inhalation powder DISKUS 250/50, tiotropium bromide inhalation powder HandiHaler
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 255 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Torrance, California + 15 more
- Conditions
- End Stage Kidney Disease, Chronic Pain
- Interventions
- Active tDCS, Sham tDCS
- Device
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 2
- States / cities
- New York, New York